Homeostatic Roles of Eosinophils in Asthma

NCT ID: NCT06676397

Last Updated: 2024-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-04

Study Completion Date

2027-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The HOMEOS study is an exploratory, observational, and monocentric research. It focuses on characterizing the homeostatic roles of eosinophils in severe asthma. The primary objective is to identify eosinophil subpopulations among different groups of severe asthmatic patients using flow cytometry. The study aims to advance understanding of eosinophil diversity, which could guide new therapeutic approaches .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma; Eosinophilic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Severe Asthma Patients : Biologic Naïves

Severe Asthma Patients : Biologic Naïves

Group Type OTHER

Blood Punction

Intervention Type PROCEDURE

venous blood sampling

Severe Asthma Patients: Responders to Biologics

Severe Asthma Patients: Responders to Biologics

Group Type OTHER

Blood Punction

Intervention Type PROCEDURE

venous blood sampling

Severe Asthma Patients: Non Responders to Biologics

Severe Asthma Patients: Non Responders to Biologics

Group Type OTHER

Blood Punction

Intervention Type PROCEDURE

venous blood sampling

Mild asthmatics

Mild asthmatics

Group Type OTHER

Blood Punction

Intervention Type PROCEDURE

venous blood sampling

Healthy Controls

Healthy Controls

Group Type OTHER

Blood Punction

Intervention Type PROCEDURE

venous blood sampling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Punction

venous blood sampling

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with mild asthma with severe asthma (Biologic-naïve, responders to anti-eosinophil biologic therapies and resistant to anti-eosinophil biologic therapies), control subjects without asthma
* Signature of informed consent
* Affiliation with the French social security system

Exclusion Criteria

* Non-eosinophilic asthma
* Coexistence of a chronic eosinophilic inflammatory condition other than asthma
* Other respiratory conditions (cystic fibrosis, COPD, allergic bronchopulmonary aspergillosis, etc.)
* Treatment with corticosteroids within 10 days prior to inclusion
* Active smoking or a smoking history of more than 20 pack-years
* Pregnant women
* Legal incapacity or limited legal capacity
* Subject unlikely to cooperate with the study and/or with anticipated low cooperation as assessed by the investigator
* Subject without health insurance
* Subject currently in an exclusion period of another study or as indicated by the "national registry of volunteers."
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cindy Barnig, MD, PhD

Role: CONTACT

+33 3 81 66 82 04

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024/877

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Molecular Mechanism of Asthma
NCT00180726 WITHDRAWN NA